First Phase III Study of Combination Molecularly Targeted Drugs in Melanoma Meets Endpoint | GenomeWeb

Originally published June 2.

CHICAGO (GenomeWeb) – Updated Phase III analysis showed that the combination of GlaxoSmithKline's BRAF inhibitor Tafinlar (dabrafenib) and MEK inhibitor Mekinist (trametinib) halted advanced melanoma patients' disease progression for three months longer than those on just Tafinlar, according to data presented at the American Society of Clinical Oncology meeting held here this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.